BR112013000841A2 - composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano. - Google Patents

composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano.

Info

Publication number
BR112013000841A2
BR112013000841A2 BR112013000841A BR112013000841A BR112013000841A2 BR 112013000841 A2 BR112013000841 A2 BR 112013000841A2 BR 112013000841 A BR112013000841 A BR 112013000841A BR 112013000841 A BR112013000841 A BR 112013000841A BR 112013000841 A2 BR112013000841 A2 BR 112013000841A2
Authority
BR
Brazil
Prior art keywords
body mass
psychoactive
treatment
mammalian body
substance addiction
Prior art date
Application number
BR112013000841A
Other languages
English (en)
Portuguese (pt)
Inventor
Sergey Alexandrovich Tarasov
Irina Anatolievna Kheyfets
Julia Alexandrovna Zabolotneva
Julia Leonidovna Dugina
Liudmila Fyodorovna Dolgovyh
Oleg Lliich Epshtein
Svetlana Alexandrovna Sergeeva
Original Assignee
Oleg Lliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013000841(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010129289/15A external-priority patent/RU2552221C2/ru
Priority claimed from RU2010130350/15A external-priority patent/RU2533224C2/ru
Priority claimed from RU2011122407A external-priority patent/RU2610438C2/ru
Application filed by Oleg Lliich Epshtein filed Critical Oleg Lliich Epshtein
Publication of BR112013000841A2 publication Critical patent/BR112013000841A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Addiction (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013000841A 2010-07-15 2011-07-15 composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano. BR112013000841A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2010129289/15A RU2552221C2 (ru) 2010-07-15 2010-07-15 Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
RU2010130350/15A RU2533224C2 (ru) 2010-07-21 2010-07-21 Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
RU2011122407A RU2610438C2 (ru) 2011-06-02 2011-06-02 Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома
PCT/IB2011/002404 WO2012007847A2 (en) 2010-07-15 2011-07-15 Pharmaceutical compositions and methods of treatment

Publications (1)

Publication Number Publication Date
BR112013000841A2 true BR112013000841A2 (pt) 2016-06-07

Family

ID=44899164

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000841A BR112013000841A2 (pt) 2010-07-15 2011-07-15 composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano.

Country Status (30)

Country Link
US (1) US8865163B2 (cg-RX-API-DMAC7.html)
EP (1) EP2593477A2 (cg-RX-API-DMAC7.html)
JP (1) JP2013535436A (cg-RX-API-DMAC7.html)
KR (1) KR20140012009A (cg-RX-API-DMAC7.html)
CN (1) CN103124742A (cg-RX-API-DMAC7.html)
AR (1) AR082246A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011278040B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013000841A2 (cg-RX-API-DMAC7.html)
CA (1) CA2805091A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000098A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2013104A3 (cg-RX-API-DMAC7.html)
DE (1) DE112011102349T5 (cg-RX-API-DMAC7.html)
DK (1) DK201370078A (cg-RX-API-DMAC7.html)
EA (1) EA029400B1 (cg-RX-API-DMAC7.html)
EE (1) EE05760B1 (cg-RX-API-DMAC7.html)
ES (1) ES2542042R1 (cg-RX-API-DMAC7.html)
FI (1) FI20135146L (cg-RX-API-DMAC7.html)
FR (1) FR2962653A1 (cg-RX-API-DMAC7.html)
GB (1) GB2496076B (cg-RX-API-DMAC7.html)
IT (1) ITTO20110641A1 (cg-RX-API-DMAC7.html)
LT (1) LT5987B (cg-RX-API-DMAC7.html)
MX (1) MX361778B (cg-RX-API-DMAC7.html)
MY (1) MY158183A (cg-RX-API-DMAC7.html)
NO (1) NO20130219A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ606768A (cg-RX-API-DMAC7.html)
PE (1) PE20131338A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500109A1 (cg-RX-API-DMAC7.html)
SE (1) SE1350179A1 (cg-RX-API-DMAC7.html)
SG (1) SG187037A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012007847A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CA2804966A1 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
CN103154028A (zh) 2010-07-15 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
ES2425314R1 (es) * 2010-07-15 2014-07-09 Oleg Iliich Epshtein Composición farmacéutica combinada y uso para preparar medicamentos destinados al tratamiento de trastornos del sistema genitourinario
SE1350212A1 (sv) * 2010-07-21 2013-04-22 Oleg Iliich Epshtein Farmaceutisk kombinationskomposition och meto der för behandling av diabetes och metabola rubbningar
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
PE20130387A1 (es) * 2010-07-21 2013-03-30 Oleg Iliich Epshtein Composicion farmaceutica y combinacion y metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria
ITTO20110630A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
RU2013111962A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
KR102731863B1 (ko) * 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
CA3000167A1 (en) * 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
ES2973183T3 (es) * 2019-08-29 2024-06-18 Oleg Iliich Epshtein Medicamento para tratar enfermedades infecciosas
CH721975A1 (de) * 2024-07-15 2026-01-30 Ilyich Epshtein Oleg Verfahren für den Erhalt von Kosmetik- und therapeutischen Kosmetikmitteln

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
WO1997028776A1 (en) 1996-02-12 1997-08-14 Oleg Iliich Epshtein Medicament and method of treating an organism with medicaments
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2209084C1 (ru) * 2001-12-26 2003-07-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения депрессивных расстройств
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
GB2414670B (en) 2003-03-14 2008-03-19 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
US20050100513A1 (en) * 2003-11-10 2005-05-12 Watkins Mary B. Homeopathic method and system for treating nicotine addiction
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007149010A1 (en) * 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
RU2437678C2 (ru) 2006-06-06 2011-12-27 Олег Ильич Эпштейн Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
RU2438707C2 (ru) 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
TW200825067A (en) 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
EP1985295A1 (en) * 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
JP2010132631A (ja) * 2008-11-04 2010-06-17 Bizen Chemical Co Ltd カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
CN103154028A (zh) 2010-07-15 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
CN103096927A (zh) 2010-07-15 2013-05-08 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及治疗胃肠道功能性疾病或病症的方法
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
SE1350212A1 (sv) 2010-07-21 2013-04-22 Oleg Iliich Epshtein Farmaceutisk kombinationskomposition och meto der för behandling av diabetes och metabola rubbningar
CA2805943A1 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein Use of homeopathically potentized antibodies to brain-specific protein s-100 and to endothelial no synthase for treating alzheimer's disease
ITTO20110634A1 (it) 2010-07-21 2012-01-22 Oleg Iliich Epshtein Metodo per trattare patologie organiche del sistema nervoso, la sindrome psicoorganica e l'encefalopatia
ITTO20110630A1 (it) 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa

Also Published As

Publication number Publication date
EP2593477A2 (en) 2013-05-22
US8865163B2 (en) 2014-10-21
FR2962653A1 (fr) 2012-01-20
SE1350179A1 (sv) 2013-04-12
MY158183A (en) 2016-09-15
KR20140012009A (ko) 2014-01-29
ES2542042R1 (es) 2015-10-06
EE201300005A (et) 2013-08-15
DE112011102349T5 (de) 2013-04-18
DK201370078A (en) 2013-02-14
US20130017202A1 (en) 2013-01-17
CN103124742A (zh) 2013-05-29
LT2013015A (lt) 2013-11-25
SG187037A1 (en) 2013-02-28
PH12013500109A1 (en) 2015-07-03
FI20135146A7 (fi) 2013-02-15
AU2011278040A1 (en) 2013-03-07
CZ2013104A3 (cs) 2013-05-29
PE20131338A1 (es) 2013-11-18
EE05760B1 (et) 2016-03-15
AU2011278040B2 (en) 2016-06-02
NO20130219A1 (no) 2013-03-22
MX361778B (es) 2018-12-17
CA2805091A1 (en) 2012-01-19
ITTO20110641A1 (it) 2012-01-16
EA029400B1 (ru) 2018-03-30
EA201300133A1 (ru) 2014-03-31
GB2496076A (en) 2013-05-01
GB201302653D0 (en) 2013-04-03
CL2013000098A1 (es) 2015-01-16
WO2012007847A2 (en) 2012-01-19
LT5987B (lt) 2014-01-27
WO2012007847A3 (en) 2012-04-12
ES2542042A2 (es) 2015-07-29
NZ606768A (en) 2015-08-28
MX2013000545A (es) 2013-10-28
FI20135146L (fi) 2013-02-15
JP2013535436A (ja) 2013-09-12
AR082246A1 (es) 2012-11-21
GB2496076B (en) 2018-05-09

Similar Documents

Publication Publication Date Title
MY158183A (en) Pharmaceutical compositions and methods of treatment
BR112012013093A2 (pt) ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
BR112013031659A2 (pt) composição para uso, método de tratamento ou profilaxia de doenças do trato respiratório em pacientes, uso de bifidobacterium lactis bl-04 e método de modificação da ingestão de medicações em pacientes
PH12013500111A1 (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
BRPI1007602A2 (pt) "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia"
BR112013001299A2 (pt) composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
PH12018500640A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
BR112014009418A2 (pt) macrociclos peptidomiméticos
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
BR112012000862A8 (pt) composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
IN2013MN00758A (cg-RX-API-DMAC7.html)
BR112012031107A2 (pt) molécula de ligação específica cultivada contra a proteína anx-a1 humana, linha de células de hibridoma, composição farmacêutica , uso da molécula de ligação específica e método para o tratamento de uma doença mediada por linfócitos t em um indivíduo com necessidade do mesmo
IL219579B (en) Use of fusion proteins for preparation of medicaments for treatment and prophylaxis of diseases of the respiratory tract
IL210204A (en) Ligand, method for preparing it, antibody and pharmaceutical composition comprising same and use thereof in the manufacture of a medicament for treating msrv-associated disease
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
BR112013015509A2 (pt) composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal farmaceuticamente aceitável do mesmo e de composição
IL217519A (en) Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders
EP3156064A4 (en) Application of yb-1 protein and fragments thereof for preparing medicinal agents in treating alzheimer's disease

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2470 DE 08-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.